2 Hot Biotechs Set Deliver Paydays to Investors in 2015

It has been a tough start to the New Year for investors. The major indexes lost between two and four percent in January. The energy sector continues to be a pariah as crude struggles to find a floor. Financials have been hit due to falling interest rates and disappointing quarterly results from the major banks. […]

Read more

3 REITs to Dump Now

REITs have been a hot sector in a volatile stock market. With share prices soaring in January, upcoming yields on these three stocks will be driven down greatly impacting every income investor owner. Now is the time to sell these stocks, take your gains, and reinvest elsewhere in the market where the yields are more […]

Read more

3 Ways to Profit from Earnings Overreactions

We’ve uncovered some noteworthy trends thanks to the earnings calls over the past two weeks. But, even more interesting is the buying opportunities that earnings overreactions have created. Great investors, once they see which stocks we profiled, will jump on the chance to purchase these stocks knowing that big returns are almost guaranteed. So far, […]

Read more

Bonds are on a Roll

Bond ETFs have been in rally mode for months and investors need to understand the opportunities and implications of these moves. Who would have thought that between September 2, 2014 and January 29, the share price of the iShares Barclays 20+ Year Treasury Bond ETF (TLT) would have soared 17.48 percent, while the share price […]

Read more

4 REITs Increasing Dividends in February

The four stocks detailed here have long histories of hiking their dividend each year, and are rock solid additions to every income investing portfolio. As a company that raises distributions each year pays many more benefits than just the extra cash in your pocket. One of the best events for income investors to enjoy is […]

Read more

Two Momentum Stocks with Triple Digit Potential

Investing in the biotech sector is a challenge, but a hard test always comes with its prize at the end. The rewards from investing in the biotech sector can be huge. Triple digit returns within a matter of months. These two stocks have all the right pieces to lead investors to the elusive triple digit winner. My […]

Read more

3 Cult Stocks to Avoid in 2015

These three stocks are defined by innovation and customers who can’t get enough, but the valuations of these stocks just don’t add up. With such sky-high valuations not based on business fundamentals, these stocks can turn sour at a moments notice. It would be wise to avoid these 3 stocks right now. Writing on a […]

Read more

3 MLPs That Will Pop 25% After Announcing Distributions

If you’re looking for one trade to make right now that can book you a 25% or higher return in less than three weeks, look no further. These 3 MLPs’ share prices have been driven down because of fears they won’t be able to keep distributions at desired levels, but Tim Plaehn’s research proves otherwise. […]

Read more

2015 Bankruptcy Watchlist: Avoid these Stocks

As promised, it is time to take a look at the companies that won’t be around come 2016. We made some bold predictions last year, and we’re doing the same for 2015 including one stalwart technology company that nobody expects. Every investor needs to shield their portfolio from these rotten eggs.  Just a few months ago […]

Read more

The Investment Case for Gold

Gold is on the move as quantitative easing sweeps the world. After calendar year 2014 brought the spot price of gold a 1.79 percent decline to $1,183.20 per ounce on the Chicago Mercantile Exchange, gold has started 2015 with a strong rally Gold’s big problem throughout 2014 was the Federal Reserve’s move to taper its […]

Read more

REITs, BDCs, MLPs: Where are the Best Income Investments for 2015?

Any proper projection for 2015 has to start with a serious review of the 2014 performance from the different categories of income stocks. All income investments are not created equally, and keeping current on the market will keep your portfolio earning money. In this article I will go over each of the three categories of […]

Read more

2 Triple Digit Winners for Under $2

I have found over three decades of investing that few areas of the market provide more potential upside than the small cap healthcare stocks that others have given up on but which have catalysts to spur their shares much higher over time. When the market ignores the future catalysts for creating shareholder value it allows […]

Read more

Halzozyme Therapeutics: A Good Bet to Get Back to Previous Highs

Our second selection this month is Halozyme Therapeutics (Nasdaq: HALO). Halozyme is a small biopharma play with a $1 billion market capitalization. Biotech and biopharma have been fascinating spaces this year and have yielded some of my best returns so far in 2014 as anyone that purchased Avanir Pharmaceuticals (Nasdaq: AVNR) in the inaugural issue […]

Read more